Bernstein, V. , Peretz, D.I.: Lidoflazine, a new drug in the treatment of angina pectoris. Curr. Ther. Res., 14: 483-495, 1972.
2.
Piessens, J. , De Geest, H.: Long-term evaluation of lidoflazine in angina pectoris based on exercise tolerance. Cardiology, 57: 135-149, 1972.
3.
Nordstrom, L.A. , Gobel, F.L.: The effect of lidoflazine on exercise tolerance in patients with angina pectoris. Chest, 74: 50-54, 1978.
4.
Jenkins, M.D. , Swallow, E.A., Kidner, P.H.: A double blind placebo controlled trial of lidoflazine in angina pectoris. Br. Heart J., in press, 1979.
5.
Gobel, F.L., Nordstrom, L.A., Nelson, R.R., et al.: Effect of lidoflazine on myocardial performance and myocardial blood flow in patients with angina pectoris. Second International Lidoflazine Symposium, Hamburg (Germany), May 9-10, 1975.
6.
Schaper, W.K.A. , Xhonneux, R., Jageneau, A.H.M., et al.: The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator. J. Pharmacol. Exp. Ther., 152: 265-274, 1966.
7.
Thomsen, J.H. , Stenlund, R.R., Corliss, R.J., et al.: The systemic and coronary hemodynamic effects of lidoflazine. Arch. Int. Pharmacodyn., 172: 15-23, 1968.
8.
Marshall, R.J. , Parratt, J.R.: Drug-induced changes in blood flow in the acutely ischaemic canine myocardium: Relationship to subendocardial driving pressure. Clin. Exp. Pharmacol. Physiol., 1: 99-112, 1974.
9.
De Cock, W., Schuermans, V., Jagenau, A., et al.: Resting, exercise and postexercise heart rate and systolic time intervals in normal men treated with lidoflazine. Arzneim. Forsch. (Drug Res.), 23: 1450-1454, 1973 .
10.
Detry, J.-M.R. , Rousseau, M.F., Filleul, P., et al.: Hemodynamic effects of lidoflazine during graded levels of bicycle exercise in normal subjects. Eur. J. Cardiol., 4: 165-174, 1976.
11.
Shepherd, J.T. , Vanhoutte, P.M.: Veins and Their Control. Philadelphia, W. B. Saunders, 1975 , pp. 1-269.
12.
Shepherd, J.T. , Vanhoutte, P.M.: The Human Cardiovascular System. Facts and Concepts. New York, Raven Press , 1979 pp. 1-351.
13.
Vanhoutte, P., Clement, D., Leusen, I.: The reactivity of isolated veins to electrical stimulation. Arch. Int. Physiol. Biochem., 75: 641-657, 1967.
14.
Vanhoutte, P., Leusen, I.: The reactivity of isolated venous preparations to electric stimulation. Pflügers Arch., 306: 341-353, 1969.
15.
De Mey, J., Vanhoutte, P.M.: Comparison of the responsiveness of cutaneous veins of dog and rabbit to adrenergic and cholinergic stimulation. Blood Vessels, in press (1980).
16.
Verbeuren, T.J., Janssens, W.J., Vanhoutte, P.M.: Effects of moderate acidosis on adrenergic neurotransmission in canine saphenous veins. J. Pharmacol. Exp. Ther., 206: 105-114, 1978.
17.
Verbeuren, T.J., Coen, E., Vanhoutte, P.M.: Determination of 3H-norepinephrine and its metabolites in superfusate from isolated blood vessels. Arch. Int. Pharmacodyn., 227: 171-174, 1977.
18.
Muldoon, S.M. , Vanhoutte, P.M., Tyce, G.M.: Norepinephrine metabolism in canine saphenous vein: Prevalence of glycol metabolites. Am. J. Physiol., 234: H235-H243, 1978.
19.
Muldoon, S.M. , Janssens, W.J., Verbeuren, T.J., et al.: Alpha-adrenergic blocking properties of droperidol on isolated blood vessels of the dog. Br. J. Anaesthesia, 49: 211-216, 1977.
20.
Türker, R.K. , Kayaalp, S.O.: Effect of lidoflazine on norepinephrine, angiotensin and serotonin responses in isolated smooth muscle preparations . Experientia, 28: 647, 1967.
21.
Godfraind, T. , Polster, P.: Etude comparative de médicaments inhibitant la réponse contractile de vaisseaux isolés d'origine humaine ou animale. Thérapie, 23: 1209-1220, 1968.
22.
Van Nueten, J.M. , Wellens, D.: Tissue specificity of calcium-antagonistic properties of lidoflazine. Arch. Int. Pharmacodyn., in press 1980.
23.
Lorenz, R.R. , Vanhoutte, P.M.: Inhibition of adrenergic neurotransmission in isolated veins of the dog by potassium ions. J. Physiol. , 246: 479-500, 1975.
24.
Vanhoutte, P.M., Verbeuren, T.J.: Inhibition by acetylcholine of the norepinephrine release evoked by potassium in canine saphenous vein. Circ. Res., 39: 263-269, 1976.
25.
Van Nueten, J.M.: Comparative bioassay of vasoactive drugs using isolated perfused rabbit arteries. Eur. J. Pharmacol. , 6: 286-293, 1969.
26.
Godfraind, T., Kaba, A.: Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol., 36: 549-560, 1969.
27.
Kosche, F., Raff, K.W., Lochner, W.: Influence of the extracellular calcium concentration on the action of coronary dilators (a contribution to the mechanism of the action of coronary dilators). PlfügersArch. Physiol., 335: 46-57, 1972.
28.
Van Nueten, J.M., Van Beek, J., Vanhoutte, P.M.: Inhibitory effect of lidoflazine on contractions of isolated canine coronary arteries caused by norepinephrine, 5-hydroxytryptamine, high potassium, anoxia and ergonovine maleate. J. Pharmacol. Exp. Ther., accepted for publication. Van Nueten, J.M., Wellens, D.: Mechanisms of vasodilatation and antivasoconstriction. Angiology, 30: 440-446, 1979.
29.
Van Nueten, J.M. : Vasodilatation or inhibition of peripheral vasoconstriction? in Mechanisms of Vasodilatation. Edited by P. M. Vanhoutte, I. Leusen.Basel, S. Karger, 1978, pp. 137-143.
30.
Van Belle, H.: The disappearance of adenosine in dog blood after low oral doses of lidoflazine (0.31-5 mg/kg). Eur. J. Pharmacol., 10: 290-292, 1970.
31.
Van Belle, H.: The disappearance of adenosine in blood. Effect of lidoflazine and other drugs. Eur. J. Pharmacol. , 11: 241-248, 1970.
32.
Afonso, S., O'Brien, G.S.: Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs. Arch. Int. Pharmacodyn., 194: 181-196, 1971.
33.
Spieckerman, P.G., Fuchs, C., Gethmann, J.W., et al.: Einfluss des Koronardilatators Lidoflazin auf den Adenosinstoffwechsel des Myokards während Ischämie und Anoxie. Arzneim. Forsch., 22: 1869-1874, 1972.
34.
De Clerck, F.F. , Reneman, R.S.: Effect of lidoflazine (R 7904) on uptake and release of serotonin by human platelets in vitro.
35.
Janssens, W.J. , Vanhoutte P.M.: Instantaneous changes of alpha-adrenoceptor affinity caused by moderate cooling in canine cutaneous veins. Am. J. Physiol., 234: H330-H337, 1978.
36.
Vanhoutte, P.M.: Effect of anoxia and glucose depletion on isolated veins of the dog. Am. J. Physiol., 230: 1261-1268, 1976.
37.
Vanhoutte, P.M. : Heterogeneity of vascular smooth muscle, in Microcirculation. Edited by G. Kaley , B. M. Altura.Baltimore, University Park Press, 1978, pp. 181-309.
38.
Vanhoutte, P.M.: Adrenergic neuroeffector interaction in the blood vessel wall. Fed. Proc., 37: 181-186, 1978.
39.
Haeusler, G. : The effect of verapamil on the contractility of smooth muscle and on excitation-secretion coupling in adrenergic nerve terminals. Angiologica, 8: 156-160, 1971.
40.
Afonso, S., O'Brien, G.S., Crumpton, W.: Enhancement of coronary vasodilating action of ATP and adenosine by lidoflazine . Circ. Res., 22: 43-48, 1968.
41.
Jageneau, A.H.M. , Schaper, W.K.A., Van Gerven , W.: Enhancement of coronary reactive hyperemia in unanaesthetized pigs by an adenosine-potentiator (lidoflazine) . Arch. Pharmacol., 265: 16-23, 1969.